These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 34503111)

  • 1. PIM Kinases in Multiple Myeloma.
    Wu J; Chu E; Kang Y
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIM Kinase as an Executional Target in Cancer.
    Zhang X; Song M; Kundu JK; Lee MH; Liu ZZ
    J Cancer Prev; 2018 Sep; 23(3):109-116. PubMed ID: 30370255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
    Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
    PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors.
    Burger MT; Han W; Lan J; Nishiguchi G; Bellamacina C; Lindval M; Atallah G; Ding Y; Mathur M; McBride C; Beans EL; Muller K; Tamez V; Zhang Y; Huh K; Feucht P; Zavorotinskaya T; Dai Y; Holash J; Castillo J; Langowski J; Wang Y; Chen MY; Garcia PD
    ACS Med Chem Lett; 2013 Dec; 4(12):1193-7. PubMed ID: 24900629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Pim kinases in multiple myeloma.
    Keane NA; Reidy M; Natoni A; Raab MS; O'Dwyer M
    Blood Cancer J; 2015 Jul; 5(7):e325. PubMed ID: 26186558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential Pharmacological Inhibitors of Pim Kinase Under Clinical Trials.
    Jeyapal GP; Chandrasekar MJN; Krishnasamy R; Selvaraj J; Mohammad M; Nanjan MJ
    Anticancer Agents Med Chem; 2018; 18(8):1100-1114. PubMed ID: 29384063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
    Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
    Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting PIM kinases in cancer therapy: An update on pharmacological small-molecule inhibitors.
    Chen S; Yang Y; Yuan Y; Bo Liu
    Eur J Med Chem; 2024 Jan; 264():116016. PubMed ID: 38071792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIM Kinase Inhibitors as Novel Promising Therapeutic Scaffolds in Cancer Therapy.
    Karati D; Saha A; Roy S; Mukherjee S
    Curr Top Med Chem; 2024; 24(28):2489-2508. PubMed ID: 39297470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
    Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
    Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma.
    Paíno T; González-Méndez L; San-Segundo L; Corchete LA; Hernández-García S; Díaz-Tejedor A; Algarín EM; Mogollón P; Martín-Sánchez M; Gutiérrez NC; Mateos MV; Garayoa M; Ocio EM
    Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32987735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma.
    Cervantes-Gomez F; Chen LS; Orlowski RZ; Gandhi V
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S317-29. PubMed ID: 23988451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC.
    Moore G; Lightner C; Elbai S; Brady L; Nicholson S; Ryan R; O'Sullivan KE; O'Byrne KJ; Blanco-Aparicio C; Cuffe S; O'Neill M; Heavey S; Finn SP; Gately K
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33946744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells.
    Cervantes-Gomez F; Stellrecht CM; Ayres ML; Keating MJ; Wierda WG; Gandhi V
    Oncotarget; 2019 Apr; 10(29):2793-2809. PubMed ID: 31073371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIM3 Kinase: A Promising Novel Target in Solid Cancers.
    Atalay P; Ozpolat B
    Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma.
    Stafman LL; Mruthyunjayappa S; Waters AM; Garner EF; Aye JM; Stewart JE; Yoon KJ; Whelan K; Mroczek-Musulman E; Beierle EA
    Oncotarget; 2018 Apr; 9(32):22665-22679. PubMed ID: 29854306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PIM family of serine/threonine kinases in cancer.
    Narlik-Grassow M; Blanco-Aparicio C; Carnero A
    Med Res Rev; 2014 Jan; 34(1):136-59. PubMed ID: 23576269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway.
    Okada K; Nogami A; Ishida S; Akiyama H; Chen C; Umezawa Y; Miura O
    Oncotarget; 2018 Feb; 9(10):8870-8886. PubMed ID: 29507660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer.
    Malone T; Schäfer L; Simon N; Heavey S; Cuffe S; Finn S; Moore G; Gately K
    Pharmacol Ther; 2020 Mar; 207():107454. PubMed ID: 31836451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Pim kinases: new targets for drug development.
    Swords R; Kelly K; Carew J; Nawrocki S; Mahalingam D; Sarantopoulos J; Bearss D; Giles F
    Curr Drug Targets; 2011 Dec; 12(14):2059-66. PubMed ID: 21777193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.